Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, MRUS, ACLX, RVMD, TARS, and represent 49.10% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$133M), GMAB (+$117M), XBI (+$100M), CDTX (+$92M), URGN (+$84M), AGIO (+$70M), MRUS (+$37M), EYPT (+$29M), TNGX (+$26M), AMLX (+$26M).
- Started 11 new stock positions in XBI, GPCR, CDTX, GMAB, DYN, TNGX, EYPT, Bridgebio Oncology Therapeut, URGN, AMLX. ABVX.
- Reduced shares in these 10 stocks: COGT (-$103M), ONC (-$84M), IRON (-$64M), MLTX (-$42M), LENZ (-$30M), Y Mabs Therapeutics (-$19M), TARS (-$18M), IMTX (-$17M), BBIO (-$15M), CBIO (-$10M).
- Sold out of its positions in ONC, MLTX, Y Mabs Therapeutics, CBIO, IMTX.
- Paradigm Biocapital Advisors was a net buyer of stock by $459M.
- Paradigm Biocapital Advisors has $3.5B in assets under management (AUM), dropping by 50.13%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 34 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 13.0 | $456M | 5.3M | 86.48 |
|
|
| Merus N V Call Option (MRUS) | 12.5 | $440M | +9% | 4.7M | 94.15 |
|
| Arcellx Common Stock (ACLX) | 10.9 | $382M | 4.6M | 82.10 |
|
|
| Revolution Medicines (RVMD) | 8.3 | $291M | +2% | 6.2M | 46.70 |
|
| Tarsus Pharmaceuticals (TARS) | 4.5 | $158M | -10% | 2.7M | 59.43 |
|
| Vaxcyte (PCVX) | 3.9 | $136M | +12% | 3.8M | 36.02 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.8 | $133M | NEW | 1.6M | 84.90 |
|
| Genmab A/s Sponsored Ads (GMAB) | 3.3 | $117M | NEW | 3.8M | 30.67 |
|
| Agios Pharmaceuticals Call Option (AGIO) | 3.3 | $115M | +151% | 2.9M | 40.14 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.0 | $106M | +8% | 2.6M | 41.65 |
|
| Spdr Series Trust S&p Biotech Put Option (XBI) | 2.8 | $100M | NEW | 1.0M | 100.20 |
|
| Edgewise Therapeutics (EWTX) | 2.8 | $100M | 6.2M | 16.22 |
|
|
| Cidara Therapeutics Com New (CDTX) | 2.6 | $92M | NEW | 961k | 95.76 |
|
| Urogen Pharma (URGN) | 2.4 | $84M | NEW | 4.2M | 19.95 |
|
| Scholar Rock Hldg Corp (SRRK) | 2.1 | $75M | +25% | 2.0M | 37.24 |
|
| Janux Therapeutics (JANX) | 2.0 | $71M | 2.9M | 24.44 |
|
|
| Olema Pharmaceuticals (OLMA) | 1.9 | $67M | 6.8M | 9.79 |
|
|
| Apogee Therapeutics (APGE) | 1.7 | $61M | +58% | 1.5M | 39.73 |
|
| Miragen Therapeutics (VRDN) | 1.6 | $56M | -4% | 2.6M | 21.58 |
|
| Alkermes SHS (ALKS) | 1.5 | $52M | +24% | 1.7M | 30.00 |
|
| Lenz Therapeutics (LENZ) | 1.4 | $50M | -37% | 1.1M | 46.58 |
|
| Pharvaris N V (PHVS) | 1.3 | $46M | +72% | 1.8M | 24.95 |
|
| Cogent Biosciences (COGT) | 1.3 | $45M | -69% | 3.2M | 14.36 |
|
| Ocular Therapeutix (OCUL) | 1.2 | $41M | +2% | 3.5M | 11.69 |
|
| Bridgebio Pharma (BBIO) | 1.0 | $36M | -29% | 684k | 51.94 |
|
| Erasca (ERAS) | 0.8 | $30M | +13% | 14M | 2.18 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.8 | $29M | NEW | 2.0M | 14.24 |
|
| Tango Therapeutics (TNGX) | 0.7 | $26M | NEW | 3.1M | 8.40 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.7 | $26M | NEW | 1.9M | 13.59 |
|
| Spyre Therapeutics Com New (SYRE) | 0.7 | $25M | -21% | 1.5M | 16.76 |
|
| Dyne Therapeutics (DYN) | 0.7 | $24M | NEW | 1.9M | 12.65 |
|
| Bridgebio Oncology Therapeut Com New | 0.6 | $22M | NEW | 1.9M | 11.58 |
|
| Disc Medicine (IRON) | 0.5 | $16M | -79% | 248k | 66.08 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.3 | $10M | NEW | 373k | 28.00 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2025 Q3 filed Nov. 14, 2025
- Paradigm Biocapital Advisors 2025 Q2 filed Aug. 14, 2025
- Paradigm Biocapital Advisors 2025 Q1 filed May 15, 2025
- Paradigm Biocapital Advisors 2024 Q4 filed Feb. 14, 2025
- Paradigm Biocapital Advisors 2024 Q3 filed Nov. 14, 2024
- Paradigm Biocapital Advisors 2024 Q2 filed Aug. 14, 2024
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022
- Paradigm Biocapital Advisors 2022 Q1 filed May 16, 2022
- Paradigm Biocapital Advisors 2021 Q4 filed Feb. 14, 2022